Prolotherapy has been used in clinical medicine for decades, yet it remains less well-known than newer regenerative options like platelet-rich plasma. For athletes and active individuals dealing with chronic joint pain that has not responded to standard treatments, it deserves a clear-eyed look at both the mechanism and the evidence.
What Is Prolotherapy?
Prolotherapy, short for proliferative therapy, is an injection-based treatment in which a solution, most commonly dextrose (sugar water) in concentrations of 10 to 25 percent, is injected into a painful joint, ligament, or tendon attachment site. The term “proliferative” refers to the goal of stimulating tissue proliferation, or regrowth, at the injection site.
The procedure has a long history, with early modern use documented in the mid-20th century. Today it is practiced primarily by physiatrists (physical medicine and rehabilitation specialists), sports medicine physicians, and some orthopedic surgeons.
How Does It Work?
The Proposed Mechanism
When dextrose is injected into tissue, it is thought to create a localized, transient inflammatory response. This controlled irritation is believed to trigger the body’s natural repair cascade: fibroblasts migrate to the area, begin producing collagen, and over time deposit new connective tissue at the injection site. The intended result is strengthened and stabilized tissue at a ligament or tendon attachment where chronic pain and laxity have developed.
A secondary mechanism proposed in some research involves the direct effect of dextrose on nociceptors (pain-sensing nerve endings), which may reduce pain signaling independently of structural changes. The exact mechanisms remain under investigation, and the evidence base continues to develop.
What the Evidence Shows
Knee Osteoarthritis
Knee osteoarthritis (OA) is one of the most studied applications of prolotherapy. A systematic review in the PM&R Journal (Physical Medicine and Rehabilitation) concluded that dextrose prolotherapy produced clinically meaningful improvements in pain, function, and stiffness in patients with knee OA, with effects maintained at follow-up periods of 6 to 12 months. The evidence was graded as moderate quality, limited by the relatively small number of high-quality randomized controlled trials available at the time.
A notable randomized controlled trial published in the Annals of Family Medicine found that participants receiving dextrose prolotherapy reported significantly greater improvements in pain and function compared to saline injection and at-home exercise alone, with the greatest benefits in those with more severe baseline pain.
Chronic Low Back Pain
The evidence for prolotherapy in chronic low back pain is more mixed. A Cochrane review found that when used in isolation, prolotherapy does not consistently outperform control injections for nonspecific low back pain. However, when combined with other therapies such as exercise or spinal manipulation, the data suggested a potential additive benefit. Prolotherapy may be more appropriate for back pain with an identifiable ligamentous or facet joint component than for nonspecific pain of uncertain origin.
Prolotherapy vs. PRP: Key Differences
Both prolotherapy and PRP are injection therapies aimed at stimulating tissue repair, but they differ in mechanism and cost. Prolotherapy uses a simple dextrose solution; PRP uses a concentrated preparation of your own blood platelets. PRP is considered biologically richer in growth factors and is generally more expensive, often costing several times more per injection than dextrose prolotherapy.
The evidence base differs as well. PRP has more high-quality trial data for specific tendinopathies like lateral epicondyle tendinopathy. Prolotherapy has a longer clinical history and a reasonable evidence base for knee OA. Some providers use both in sequence or combination depending on the injury and patient response. Neither should be viewed as superior across all conditions; the choice depends on the specific diagnosis, provider expertise, and the patient’s clinical context.
Treatment Frequency and What to Expect
Prolotherapy is typically delivered as a series of injections rather than a single treatment. Most protocols involve 3 to 6 sessions spaced 2 to 6 weeks apart. The injection itself involves multiple passes into the target area, which can be uncomfortable; local anesthetic is typically mixed into the solution to reduce procedural pain. Post-injection soreness lasting 24 to 72 hours is common and expected.
Patients are generally advised to avoid NSAIDs around the time of treatment, as suppressing the inflammatory response may counteract the intended proliferative mechanism. Light activity is often encouraged to promote healing, but high-impact loading of the injected area is restricted for a short period following each session.
Meaningful improvement in pain and function is typically assessed after the full injection series is complete. Some patients see gradual benefit beginning after 2 to 3 sessions; others require the full course. A structured rehabilitation program alongside the injections is considered best practice.
Who Is an Appropriate Candidate?
Prolotherapy is best suited for athletes and active individuals with chronic joint pain (typically lasting more than 3 to 6 months) at a specific anatomical site, particularly where ligamentous laxity, tendon attachment pain, or mild to moderate osteoarthritis is involved. Candidates should have tried and not adequately responded to first-line conservative care including physical therapy and activity modification.
It is generally contraindicated in the presence of acute infection, blood clotting disorders, or allergy to components of the injection solution. A thorough evaluation by a sports medicine or physiatry provider is essential to confirm the diagnosis and determine whether prolotherapy is the appropriate next step.
For a full review of the current evidence base, refer to published systematic reviews available on PubMed.
Ready to optimize your performance? Start here or contact our team.